Personalis, Inc. (NASDAQ:PSNL) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Personalis, Inc. (NASDAQ:PSNL) have been given a consensus rating of “Moderate Buy” by the eight analysts that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $10.5714.

A number of analysts recently commented on the company. Wall Street Zen lowered Personalis from a “hold” rating to a “sell” rating in a research note on Saturday, January 3rd. HC Wainwright raised their target price on shares of Personalis from $8.50 to $10.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. Morgan Stanley boosted their price target on shares of Personalis from $9.00 to $11.00 and gave the company an “equal weight” rating in a research report on Monday, December 1st. BTIG Research restated a “buy” rating and issued a $12.00 price objective on shares of Personalis in a report on Friday, January 9th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Personalis in a report on Wednesday, October 8th.

Personalis Price Performance

NASDAQ PSNL opened at $9.89 on Tuesday. Personalis has a 1 year low of $2.83 and a 1 year high of $11.40. The stock has a market capitalization of $878.23 million, a PE ratio of -11.24 and a beta of 1.96. The business’s 50-day moving average is $8.88 and its 200 day moving average is $7.39.

Personalis (NASDAQ:PSNL) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.04. The business had revenue of $14.50 million during the quarter, compared to analysts’ expectations of $13.31 million. Personalis had a negative return on equity of 38.25% and a negative net margin of 106.92%. As a group, equities research analysts anticipate that Personalis will post -1.4 earnings per share for the current year.

Insiders Place Their Bets

In other news, CFO Aaron Tachibana sold 103,668 shares of the company’s stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $10.78, for a total value of $1,117,541.04. Following the sale, the chief financial officer directly owned 164,458 shares of the company’s stock, valued at $1,772,857.24. This represents a 38.66% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Christopher M. Hall sold 29,612 shares of Personalis stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $8.99, for a total transaction of $266,211.88. Following the transaction, the chief executive officer directly owned 148,486 shares of the company’s stock, valued at approximately $1,334,889.14. This trade represents a 16.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 3.80% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Personalis

Several large investors have recently made changes to their positions in PSNL. Legal & General Group Plc purchased a new stake in shares of Personalis in the 2nd quarter worth approximately $30,000. Ameritas Investment Partners Inc. purchased a new stake in shares of Personalis in the second quarter worth $34,000. BNP Paribas Financial Markets increased its holdings in shares of Personalis by 406.4% during the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock valued at $42,000 after acquiring an additional 5,177 shares in the last quarter. Focus Partners Wealth bought a new position in shares of Personalis during the first quarter valued at $47,000. Finally, Farther Finance Advisors LLC purchased a new position in shares of Personalis in the 3rd quarter worth about $66,000. 61.91% of the stock is currently owned by hedge funds and other institutional investors.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.